Skip to main content

Advertisement

SpringerLink
Log in

A review of patient self-report tools for chemotherapy-induced nausea and vomiting

  • Review Article
  • Published:
Supportive Care in Cancer Aims and scope Submit manuscript

Abstract

Goals of work

The assessment of chemotherapy-induced nausea, vomiting and retching (CINVR) is important and to date no review has comprehensively assessed available patient self-report tools. The aim was to undertake a review of their utility, content and psychometric properties.

Materials and methods

One thousand three hundred and forty-seven citations were identified by electronic and hand searches resulting in 24 non-duplicate abstracts, 15 articles for analysis, and six articles, which fitted the inclusion criteria. E-mail investigations discovered a further scale, resulting in seven measures.

Results

The review highlighted the strengths and weaknesses of current tools. The multiple domains, phases and aspects of CINVR signify that the assessment tools varied markedly. The diverse requirements of research and clinicians also contribute to the variation. There was a notable disparity in the quality of scales and paucity in terms of their development and psychometric evaluation. We found that several self-assessment scales currently perceived as well-validated tools have problems in terms of their validity, reliability and appropriateness.

Conclusions

The constituents of a scale relevant for both clinical and research use were assessed and it was recommended that a modular tool focusing on two domains (nausea and vomiting); two phases (acute and delayed); measuring the aspects of occurrence, frequency, intensity alongside duration and functional interference; and antiemetic use and adverse events should be developed. Based on these recommendations, further research into an appropriate scale would minimise conceptual confusion, increase clinicians’ understanding and control of CINVR, decrease patient distress and could have equal utility in both a clinical and a research setting.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, Kaasa S, Klee MC, Osoba D, Razavi D, Rofe PB, Schraub S, Sneeuw KC, Sullivan M, Takeda D (1993) The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365–376

    Article  PubMed  CAS  Google Scholar 

  2. Alves-Guerreiro J, Lowe-Strong AS, Walsh DM, Lopes BC, Costa R, Rosado R, Monforte E, Rolo T, Projecto J, Ferreira M (2003) Development of a Portuguese version of the Morrow Assessment of Nausea and Emesis (MANE) questionnaire: moving physical therapy forward [abstract]. 14th International World Confederation for Physical Therapy Congress

  3. Bergkvist K, Wengström Y (2006) Symptom experience during chemotherapy treatment—with focus on nausea and vomiting. Eur J Oncol Nurs 10:21–29

    Article  PubMed  Google Scholar 

  4. Carnrike CLM Jr, Carey MP (1990) Assessing nausea and vomiting in adult chemotherapy patients: review and recommendations. Ann Behav Med 12:79–85

    Article  Google Scholar 

  5. Carnrike CLM, Brantley PJ, Bruce B, Faruqui S, Gresham FM, Buss RR, Cocke TB (1988) Test–restest reliability and concurrent validity of the Morrow Assessment of Nausea and Emesis (MANE) for the assessment of cancer chemotherapy- related nausea and vomiting. J Psychopathol Behav Assess 10:107–116

    Article  Google Scholar 

  6. Chou F-H, Avant KC, Kuo S-H, Cheng HF (2005) Assessing the psychometric and language equivalency of the Chinese versions of the index of nausea, vomiting and retching, and the prenatal self-evaluation questionnaire. Kaohsiung J Med Sci 21:314–321

    Article  PubMed  Google Scholar 

  7. Crucitt MA, Hyman W, Grote T, Tester W, Madajewicz S, Yee S, Wentz A, Griffin D, Parasuraman TV, Bryson J (1996) Efficacy and tolerability or oral ondansetron versus prochlorperazine in the prevention of emesis associated with cyclophosphomide-based chemotherapy and maintenance of health-related quality of life. Clin Ther 18:778–788

    Article  PubMed  CAS  Google Scholar 

  8. Coates AS, Abraham S, Kaye SB, Sowerbutts T, Frewin C, Fox R, Tattersall M (1983) On the receiving end: patient perception of the side effects of chemotherapy. Eur J Cancer Clin Oncol 19:203–208

    Article  PubMed  CAS  Google Scholar 

  9. de Boer-Dennert M, de Wit R, Schmitz PI, Djontono J, v Beurden V, Stoter G, Verweij J (1997) Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists. Br J Cancer 76:1055–1061

    PubMed  Google Scholar 

  10. Decker GM, DeMeyer ES, Kisko DL (2006) Measuring the maintenance of daily life activities using the functional living index-emesis (FLIE) in patients receiving moderately emetogenic chemotherapy. J Support Oncol 4:35–41

    PubMed  Google Scholar 

  11. DeGroot T, Einhorn L, Brames J, Roth BJ, Dreicer R, Nichols C, Bubalo J (2006) Multiple-day Palonosetron antiemetic regimen is safe and effective for preventing chemotherapy-induced nausea and vomiting in patients receiving 5-day Cisplatin for testicular cancer. Presented at Chicago Supportive Oncology Conference Sept 27–30

  12. Dibble SL, Chapman J, Mack KA, Shih A (2000) Acupressure for nausea: results of a pilot study. Oncol Nurs Forum 27:41–47

    PubMed  CAS  Google Scholar 

  13. Dibble SL, Israel J, Nussey B, Casey K, Luce J (2003) Delayed chemotherapy-induced nausea in women treated for breast cancer. Oncol Nurs Forum 30:40–47

    Article  Google Scholar 

  14. Farley PA, Dempsey CL, Shillington AA, Kulis-Robitaille C, Colgan K, Bernstein G (1997) Patients’ self-reported functional status after granisetron or ondansetron therapy to prevent chemotherapy-induced nausea and vomiting at six cancer centers. Am J Health-Syst Pharm 54:2478–2482

    PubMed  CAS  Google Scholar 

  15. Fromme EK, Eilers KM, Mori M, Hsieh Y-C, Beer TM (2004) How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient- reported symptoms form the quality-of-life questionnaire C30. J Clin Oncol 22:3485–3490

    Article  PubMed  Google Scholar 

  16. Fu MR, Rhodes V, Xu B (2002) The Chinese translation of the index of nausea, vomiting and retching. Cancer Nurs 25:134–140

    Article  PubMed  Google Scholar 

  17. Glaus A, Knipping C, Morant R, Bohme C, Lebert B, Beldermann F, Glawogger B, Ortega PF, Husler A, Deuson R (2004) Chemotherapy-induced nausea and vomiting in routine practice: a European perspective. Support Care Cancer 12:708–715

    Article  PubMed  Google Scholar 

  18. Gift AG, Jablonski A, Stommel M, Given WC (2004) Symptom clusters in elderly patients with lung cancer. Oncol Nurs Forum 31:203–209

    Article  Google Scholar 

  19. Griffin AM, Butow PN, Coates AS, Childs AM, Ellis PM, Dunn SM, Tattersall MHN (1996) On the receiving end v: patient perceptions of the side effects of chemotherapy in 1993. Ann Oncol 7:189–195

    PubMed  CAS  Google Scholar 

  20. Grunberg SM, Deuson RR, Mavros P, Geling O, Hansen M, Cruciani G, Daniele B, De Pouvourville G, Rubenstein EB, Daugaard G (2004) Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer 100:2261–2268

    Article  PubMed  Google Scholar 

  21. Hesketh PJ, Gralla RJ, du Bois A, Tonato M (1998) Methodology of antiemetic trials: response assessment, evaluation of new agents and definition of chemotherapy emetogenicity. Support Care Cancer 6:221–227

    Article  PubMed  CAS  Google Scholar 

  22. Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R, Chawla SP, Carides AD, Ianus J, Elmer ME, Evans JK, Beck K, Reines S, Horgan KJ (2003) The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin. J Clin Oncol 21:4112–4119

    Article  PubMed  CAS  Google Scholar 

  23. Hesketh PJ, Kris MG, Grunberg SM, Beck T, Hainsworth JD, Harker G, Aapro AM, Gandara D, Lindley C (1997) Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 15:103–109

    PubMed  CAS  Google Scholar 

  24. Hickok JT, Roscoe JA, Morrow GR, King DK, Atkins JN, Fitch TR (2003) Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5 hydroxytryptamine-3 antiemetics: a University of Rochester James P. Wilmot Cancer Center Community Clinical Oncology Program Study of 360 cancer patients treated in the community. Cancer 1:2880–2886

    Article  CAS  Google Scholar 

  25. Hickock JT, Roscoe JA, Morrow GR, Stern RM, Yang B, Flynn PJ, Kirshner HE, Rosenbluth R (1999) Use of 5-HT3 receptor antagonists to prevent nausea and emesis caused by chemotherapy for patients with breast carcinoma in community practice settings. Cancer 86:64–71

    Article  Google Scholar 

  26. Honea N, Breant J, Beck SL (2007) Treatment related symptom cluster. Semin Oncol Nurs 23:142–151

    Article  PubMed  Google Scholar 

  27. Huschka M, Burger K (2006) Does QOL provide the same information as toxicity data? Curr Probl Cancer 30:244–254

    Article  PubMed  Google Scholar 

  28. Kim YJ, Kim JY, Choi IR, Kim MW, Rhodes V (2000) The index of nausea, vomiting and retching (Korean Translation). Korean Acad Adult Nurs 12:278–285

    Google Scholar 

  29. Kobayashi K, Ishihara Y, Nukariya N, Niitani H, Furue H, Joint Research Group for Tropisetron Double-Blind Comparative Study (1999) Effects of an antiemetic drug (Tropisetron) on a quality of life during chemotherapy: use of a diary-type questionnaire and application of summary measures for assessment in a randomized, multicentre study. Respirology 4:229–238

    Article  PubMed  CAS  Google Scholar 

  30. Lebeau B, Depierre A, Giovanni M, Riviere A, Kaluzinski L, Votan B, Hédouin M, d’Allens H (1997) The efficacy of a combination of ondansetron, methylprednisolone and metopimazine in patients previously uncontrolled with a dual antiemetic treatment in cisplatin-based chemotherapy. Ann Oncol 8:887–892

    Article  PubMed  CAS  Google Scholar 

  31. Lindley CM, Hirsch JD, O’Neill CV, Transau MC, Gilbert CS, Osterhaus JT (1992) Quality of life consequences of chemotherapy-induced emesis. Qual Life Res 1:331–340

    Article  PubMed  CAS  Google Scholar 

  32. Lo LH, Hayman LL (1999) Parents associated with children in measuring acute and delayed nausea and vomiting. Nurs Health Sci 1:155–161

    Article  PubMed  CAS  Google Scholar 

  33. Martin A, Pearson J, Cai B, Elmer M, Horgan K, Lindley CM (2000) Validation of a 5-day recall version of the Functional Living Index-Emesis (FLIE) quality of life questionnaire for chemotherapy-induced emesis. Qual Life Res 9:18

    Google Scholar 

  34. Martin AR, Pearson JD, Cai B, Elmer M, Horgan K, Lindley C (2003) Assessing the impact of chemotherapy-induced nausea and vomiting on patients’ daily lives: a modified version of the Functional Living Index-Emesis (FLIE) with 5-day recall. Support Care Cancer 11:522–527

    Article  PubMed  CAS  Google Scholar 

  35. Martin AR, Carides AD, Pearson JD, Elmer M, Schmidt C, Cai B, Grunberg SM (2003) Functional relevance of antiemetic control—experience using the FLIE questionnaire in a randomised study of the NK-1 antagonist aprepitant. Eur J Cancer 39:1395–1401

    Article  PubMed  CAS  Google Scholar 

  36. Martin CG, Rubenstein EB, Elting LS, Kim YJ, Osoba D (2003) Measuring chemotherapy-induced nausea and emesis. Psychometric properties of a quality of life questionnaire. Cancer 98:645–655

    Article  PubMed  Google Scholar 

  37. Miller M, Kearney N (2004) Chemotherapy-related nausea and vomiting- past reflections, present practice and future management. Eur J Cancer Care 13:71–81

    Article  CAS  Google Scholar 

  38. Molassiotis A, Börjeson S (2006) Nausea and vomiting. In: Kearney N, Richardson A (eds) Nursing patients with cancer: principles and practice. Edinburgh, Elsevier Churchill Livingstone, pp 415–43

    Google Scholar 

  39. Molassiotis A, Saunders M, Valle J, Wilson G, Lorigan P, Wardley A, Levine E, Cowan R, Loncaster J, Rittenberg C (2008) A prospective observational study of chemotherapy-induced nausea and vomiting in routine practice in a UK cancer centre. Support Care Cancer 16:201–208

    Google Scholar 

  40. Molassiotis A, Coventry PA, Stricker CT, Clements C, Eaby B, Velders L, Rittenberg C, Gralla RJ (2007) Validation and psychometric assessment of a short clinical scale to measure chemotherapy-induced nausea and vomiting: the MASCC Antiemesis Tool (MAT). J Pain Symptom Manage 34:148–159

    Article  PubMed  Google Scholar 

  41. Molassiotis A, Helin AM, Dabbour R, Hummerston S (2007) The effects of P6 acupressure in the prophylaxis of chemotherapy-induced nausea and vomiting in breast cancer patients. Comp Ther Med 15:3–7

    Article  CAS  Google Scholar 

  42. Molassiotis A, Yung HP, Yam BM, Chan FY, Mok TS (2002) The effectiveness of progressive muscle relaxation training in managing chemotherapy-induced nausea and vomiting in Chinese breast cancer patients. A randomised controlled trial. Support Care Cancer 10:237–246

    Article  PubMed  Google Scholar 

  43. Morrow G (1984) Methodology in behavioural and psychosocial cancer research. The assessment nausea and vomiting. Past problems, current issues, and suggestions for future research. Cancer 53(Suppl):2267–2278

    PubMed  CAS  Google Scholar 

  44. Morrow G (1992) A patient report measure for the quantification of chemotherapy induced nausea and emesis: psychometric properties of the Morrow assessment of nausea and emesis (MANE). Br J Cancer 66(Suppl XIX):S72–S74

    Google Scholar 

  45. Mullin SM, Fletcher DM, Tyler LS (1998) Mail-in questionnaire for monitoring nausea and vomiting in oncology outpatients. Am J Health-Syst Pharm 55:1903–1906

    PubMed  CAS  Google Scholar 

  46. Olver IN, Matthews JP, Bishop JF, Smith RA (1994) The roles of patient and observer assessments in anti-emetic trials. Eur J Cancer 30:1223–1227

    Article  Google Scholar 

  47. Osoba D (1994) Lessons learned from measuring health-related quality of life in oncology. J Clin Oncol 12:608–616

    PubMed  CAS  Google Scholar 

  48. Osoba D, Zee B, Warr D, Latreille J, Kaizer L, Pater J (1997) Effect of postchemotherapy nausea and vomiting on health-related quality of life. Support Care Cancer 5:307–313

    Article  PubMed  CAS  Google Scholar 

  49. Osoba D, Zee B, Pater J, Warr D, Latreille J, Kaizer L (1997) Determinants of postchemotherapy nausea and vomiting in patients with cancer. J Clin Oncol 15:116–123

    PubMed  CAS  Google Scholar 

  50. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Guoguang JM, Eldridge K, Hipple A, Evans JK, Horgan KJ, Lawson F (2003) Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting: Results form a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 97:3090–3097

    Article  PubMed  CAS  Google Scholar 

  51. Presant CA (1984) Quality of life in cancer patients. Who measures what? Am J Clin Oncol 7:571–573

    Article  PubMed  CAS  Google Scholar 

  52. Rhodes VA, Watson PM, Johnson MH (1984) Development of reliable and valid measures of nausea and vomiting. Cancer Nurs 7:33–41

    Article  PubMed  CAS  Google Scholar 

  53. Rhodes VA, McDaniel RW (1997) Measuring nausea, vomiting and retching. In: Frank-Stromborg M, Olsen SJ (eds) Instruments for clinical health-care research,. 2nd edn. Jones & Bartlett, Boston, pp 509–518

    Google Scholar 

  54. Rhodes VA, McDaniel RW (1999) The index of nausea, vomiting, and retching: a new format of the lndex of nausea and vomiting. Oncol Nurs Forum 26:889–894

    PubMed  CAS  Google Scholar 

  55. Roscoe JA, Morrow GR, Hickok JT, Stern RM (2000) Nausea and vomiting remain a significant clinical problem: trends over time in controlling chemotherapy-induced nausea and vomiting in 1413 patients treated in community clinical practices. J Pain Symptom Manage 20:113–121

    Article  PubMed  CAS  Google Scholar 

  56. Sarna L (1998) Effectiveness of structured nursing assessment of symptom distress in advanced lung cancer. Oncol Nurs Forum 25:1041–1048

    PubMed  CAS  Google Scholar 

  57. Satou A, Yamazaki T, Nukariya N, Nakamachi M, Shimada K, Matsukawa M, Kurihara M (2002) Development of a Japanese version of the FLIE. Japanese Journal of Cancer and Chemotherapy 28:281–291

    Google Scholar 

  58. Schipper H, Clinch J, McMurray A, Levitt M (1984) Measuring the quality of life of cancer patients: the functional living index-cancer: development and validation. J Clin Oncol 2:472–483

    PubMed  CAS  Google Scholar 

  59. Schwartzberg L (2006) Chemotherapy-induced nausea and vomiting: state of the art in 2006. J Support Oncol 4:3–8

    PubMed  CAS  Google Scholar 

  60. Smith HS (2005) A receptor-based paradigm of nausea and vomiting. J Cancer Pain Symptom Pall 1:11–23

    Article  Google Scholar 

  61. Streiner DL (1993) A checklist for evaluating the usefulness of rating scales. Can J Psychiatry 38:140–148

    PubMed  CAS  Google Scholar 

  62. Streiner DL, Norman GR (1995) Health measurement scales: a practical guide to their development and use, 2nd edn. Oxford University Press, New York

    Google Scholar 

  63. Sykes AJ, Kiltie AE, Stewart AL (1997) Ondasetron versus a chlorpromazine and dexamethasone combination for the prevention of nausea and vomiting: a prospective, randomised study to assess efficacy, cost effectiveness and quality of life following single-fraction radiotherapy. Support Care Cancer 5:500–503

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The authors wish to thank Peter A. Coventry for his helpful critique of the review.

Author information

Authors and Affiliations

  1. School of Nursing, Midwifery and Social Work, University of Manchester, University Place, Oxford Road, Manchester, M13 9PL, UK

    Sarah G. Brearley & Alex Molassiotis

  2. Centre for Suicide Prevention, University of Manchester, University Place, Oxford Road, Manchester, M13 9PL, UK

    Caroline V. Clements

Authors
  1. Sarah G. Brearley
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Caroline V. Clements
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alex Molassiotis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sarah G. Brearley.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Brearley, S.G., Clements, C.V. & Molassiotis, A. A review of patient self-report tools for chemotherapy-induced nausea and vomiting. Support Care Cancer 16, 1213–1229 (2008). https://doi.org/10.1007/s00520-008-0428-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00520-008-0428-y

Keywords

Search

Navigation